Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.7.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2016
Dec. 31, 2015
Current assets    
Cash $ 14,305 $ 7,851
Total current assets 14,305 7,851
Total Assets 14,305 7,851
Current liabilities    
Accounts payable 349,849 622,129
Accrued interest payable 302,834 182,678
Notes payable - current - related parties 627,022 489,095
Notes payable - current, net 163,574 157,324
Derivative liability 180,038
Stock subscription payable 28,081 55,882
Related party payables 1,111,754 412,656
Other payables 263,033 242,612
Total current liabilities 3,026,185 2,162,376
Total Liabilities 3,026,185 2,162,376
Stockholders' Deficit    
Preferred stock, $.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of December 31, 2016 and December 31, 2015, respectively
Series A Convertible Preferred stock, $.00001 par value; 3,000,000 shares authorized, No shares issued or outstanding as of December 31, 2016 and December 31, 2015,
Common stock, $.00001 par value; 100,000,000 shares authorized; 67,751,068 and 60,251,068 shares issued and outstanding as of December 31, 2016 and December 31, 2015, 677 602
Additional paid in capital 14,095,430 14,353,628
Accumulated deficit (17,064,086) (16,468,956)
Total Transbiotec, Inc. stockholders' deficit (2,967,979) (2,114,726)
Noncontrolling interest (43,901) (39,799)
Total Stockholders' Deficit (3,011,880) (2,154,525)
Total Liabilities and Stockholders' Deficit $ 14,305 $ 7,851